Breast Cancer Drug Tamoxifen May Decrease Mania Of Bipolar Disorder
The drug tamoxifen is usually used to treat breast cancer, butresearchers say that it also may reduce symptoms of mania in peoplewith bipolar disorder. An article summarizing the small, three-weektrial of tamoxifen is published in Archives of GeneralPsychiatry.
New Clues For Uncovering The Mysteries Of Mental Illness
Scientists have discovered epigenetic changes (i.e. chemical changes to a gene that do not alter the DNA sequence) in individuals with schizophrenia and bipolar disorder. This is the first epigenome-wide investigation in psychiatric research, and this groundbreaking data may be a significant step on the journey to fully understanding major psychosis.
New Mouse Model Of Bipolar Disorder
Bipolar Disorder (BPD or manic-depressive illness) is one of the most serious of all mental disorders, affecting millions of individuals worldwide. Affected individuals alternate between states of deep depression and mania. While depression is characterized by persistent and long-term sadness or despair, mania is a mental state characterized by great excitement, flight of ideas, a decreased need for sleep, and, sometimes, uncontrollable behavior, hallucinations, or delusions.
Famous Bipolar People Contest Raises Awareness, Encourages Research
Famous bipolar people include some of the world's foremost musicians, actors, writers, composers and scientists. A new contest launched on YouTube uses the current interest in bipolar celebrities to raise awareness about bipolar disorder. The Famous Bipolar People Contest encourages research and reflection.
European Marketing Authorization For Abilify - For Severe Manic Episodes In Bipolar I Disorder
On April 8, 2008, the European Commission made a decision to allow thedrug ABILIFY (aripiprazole) to be marketed. ABILIFY treats moderate tosevere manic episodes for patients with Bipolar I Disorder and it isdesigned to prevent new manic episodes in patients who experiencepredominately manic episodes.
AstraZeneca Announces First Presentation Of Pivotal SEROQUEL XR TM Bipolar Studies
New pivotal trial data from two clinical studies with SEROQUEL XR™ (quetiapine fumarate) once daily Extended Release Tablets were presented today at the Eighth International Review of Bipolar Disorder (IRBD) Conference in Copenhagen, Denmark..
Supplemental New Drug Application For RISPERDAL R CONSTA R Submitted To The FDA For The Treatment Of Frequently Relapsing Bipolar Disorder
Alkermes, Inc. (NASDAQ: ALKS) announced that its partner, Johnson & Johnson Pharmaceutical Research & Development, L.L.C. (J&JPRD), submitted a Supplemental New Drug Application (sNDA) for RISPERDAL CONSTA [(risperidone) Long-Acting Injection] to the U.
Problems Identified With Diagnosis Of Bipolar Disorder
A new study by Rhode Island Hospital and Brown University researchers reports that fewer than half the patients previously diagnosed with bipolar disorder received a diagnosis of bipolar disorder based on a comprehensive, psychiatric diagnostic interview - -the Structured Clinical Interview for DSM-IV (SCID).
ABILIFY R aripiprazole Receives Expanded Indications For Maintenance Treatment In Pediatric Patients With Bipolar Disorder And Schizophrenia
Otsuka Pharmaceutical Co., Ltd. and Bristol-Myers Squibb Company (NYSE: BMY) announced that ABILIFY (aripiprazole) received expanded indications in Bipolar I Disorder and Schizophrenia. ABILIFY is now indicated for maintenance treatment of manic and mixed episodes associated with Bipolar I Disorder with or without psychotic features in pediatric patients (aged 10-17) and maintenance treatment of Schizophrenia in adolescents (aged 13-17).
FDA Approves Astrazeneca's Seroquel For Maintenance Treatment In Bipolar Disorder
AstraZeneca announced that the U.S. Food and Drug Administration (FDA) has approved SEROQUEL (quetiapine fumarate) for the maintenance treatment of patients with bipolar I disorder, as adjunct to lithium or divalproex. SEROQUEL is approved by the FDA for the treatment of schizophrenia, and is also the only single agent approved by the FDA for the treatment of both depressive episodes in bipolar disorder and acute manic episodes associated with bipolar I disorder1, 2.